IL287536B2 - Compositions and methods for using cannabinoids for neuroprotection - Google Patents

Compositions and methods for using cannabinoids for neuroprotection

Info

Publication number
IL287536B2
IL287536B2 IL287536A IL28753621A IL287536B2 IL 287536 B2 IL287536 B2 IL 287536B2 IL 287536 A IL287536 A IL 287536A IL 28753621 A IL28753621 A IL 28753621A IL 287536 B2 IL287536 B2 IL 287536B2
Authority
IL
Israel
Prior art keywords
cannabinoids
neuroprotection
compositions
methods
Prior art date
Application number
IL287536A
Other languages
English (en)
Hebrew (he)
Other versions
IL287536A (en
IL287536B1 (en
Inventor
Eric Hsu
Ujendra Kumar
Rishi Kumar Somvanshi
Shenglong Zou
Original Assignee
Inmed Pharmaceuticals Inc
Eric Hsu
Ujendra Kumar
Rishi Kumar Somvanshi
Shenglong Zou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmed Pharmaceuticals Inc, Eric Hsu, Ujendra Kumar, Rishi Kumar Somvanshi, Shenglong Zou filed Critical Inmed Pharmaceuticals Inc
Publication of IL287536A publication Critical patent/IL287536A/en
Publication of IL287536B1 publication Critical patent/IL287536B1/en
Publication of IL287536B2 publication Critical patent/IL287536B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL287536A 2019-04-24 2020-04-24 Compositions and methods for using cannabinoids for neuroprotection IL287536B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (3)

Publication Number Publication Date
IL287536A IL287536A (en) 2021-12-01
IL287536B1 IL287536B1 (en) 2025-11-01
IL287536B2 true IL287536B2 (en) 2026-03-01

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287536A IL287536B2 (en) 2019-04-24 2020-04-24 Compositions and methods for using cannabinoids for neuroprotection

Country Status (11)

Country Link
US (1) US20230043428A1 (https=)
EP (1) EP3958856A4 (https=)
JP (1) JP7633179B2 (https=)
KR (1) KR20220080045A (https=)
CN (1) CN114007603A (https=)
AU (1) AU2020261515B2 (https=)
CA (1) CA3134764A1 (https=)
IL (1) IL287536B2 (https=)
MX (1) MX2021012960A (https=)
SG (1) SG11202111809XA (https=)
WO (1) WO2020215164A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
WO2024091653A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism
WO2024148117A2 (en) * 2023-01-04 2024-07-11 Florascience Inc. Methods of treating neurodegenerative diseases or conditions
WO2025090133A1 (en) * 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018205022A1 (en) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2640379A4 (en) * 2010-11-18 2014-08-13 Pier Pharmaceuticals LOW DOSED CANNABINOIDARY MEDICINES
BR122021018502B1 (pt) * 2014-10-21 2022-05-03 United Cannabis Corp Formulação de canabinoide líquida
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
US20160282371A1 (en) * 2015-03-28 2016-09-29 Quantalytical Labs Inc. Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
CN109963595B (zh) * 2016-10-11 2023-02-03 Gbs全球生物制药公司 用于治疗神经退行性疾病的含有大麻素的复合混合物
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
WO2018205038A1 (en) * 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018205022A1 (en) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KABIRI MARYAM ET AL:, A STIMULUS-RESPONSIVE, IN SITU-FORMING, NANOPARTICLE-LADENHYDROGEL FOR OCULAR DRUG DELIVERY, 5 March 2018 (2018-03-05) *

Also Published As

Publication number Publication date
IL287536A (en) 2021-12-01
AU2020261515A1 (en) 2021-11-18
WO2020215164A1 (en) 2020-10-29
EP3958856A4 (en) 2023-01-25
US20230043428A1 (en) 2023-02-09
SG11202111809XA (en) 2021-11-29
IL287536B1 (en) 2025-11-01
JP2022530471A (ja) 2022-06-29
JP7633179B2 (ja) 2025-02-19
AU2020261515B2 (en) 2025-10-23
KR20220080045A (ko) 2022-06-14
EP3958856A1 (en) 2022-03-02
CN114007603A (zh) 2022-02-01
MX2021012960A (es) 2022-01-04
CA3134764A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
GB2614634B (en) Cannabinoid compositions and methods of using
IL276135A (en) Preparations and methods of use
SG11202111809XA (en) Compositions and methods for use of cannabinoids for neuroprotection
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL269590A (en) Methods and compositions for reducing immunogenicity
GB202105087D0 (en) Microbial compositions and methods of use
SG11202011041YA (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
IL275739A (en) Preparations for cryopreservation and methods of their use
GB2597170B (en) Diluents for compositions of cannabinoids and uses thereof
EP3606493A4 (en) DENTAL CEMENT COMPOSITIONS AND METHOD OF USE
IL287797A (en) Oligosaccharide preparations and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL283950A (en) Methods and compositions for creating cannabinoids
EP3285755A4 (en) Compositions and methods for neuroprotection and treatment of neurodegeneration
IL276680B1 (en) Silica fiber preparations and methods of use
EP4054514A4 (en) COMPOSITIONS CONTAINING FENCHOLES AND METHOD OF USE
EP3843721A4 (en) OPHTHALMIC COMPOSITIONS AND METHODS OF USE
EP3773497A4 (en) OXYTOCIN COMPOSITIONS AND METHODS OF USE
IL285367A (en) Methods and compounds for inhibiting the expression of cyp27a1
IL291538A (en) Anti-aging preparations and methods of using them
HK40065278A (en) Nanotransposon compositions and methods of use
HK40065159A (en) Sirt1-sarna compositions and methods of use
HK40049684A (en) Bismuth-thiol compositions and methods of use
AU2019903896A0 (en) Compositions and methods of use
HK40042765B (en) Sirt1-sarna compositions and methods of use